Alexander McGirr1,2,3, Daniel J Devoe1,2,3, Amelie Raedler1,2,3, Chantel T Debert2,4, Zahinoor Ismail1,2,3,4, Marcelo T Berlim5,6. 1. Department of Psychiatry, 70401University of Calgary, Alberta, Canada. 2. Hotchkiss Brain Institute, 70401University of Calgary, Alberta, Canada. 3. Mathison Centre for Mental Health Research and Education, Calgary, Alberta, Canada. 4. Department of Clinical Neuroscience, 70401University of Calgary, Alberta, Canada. 5. Department of Psychiatry, 5620McGill University, Montreal, Quebec, Canada. 6. Douglas Mental Health University Institute, Montreal, Quebec, Canada.
Abstract
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment modality for Post-traumatic stress disorder (PTSD). Several targets and stimulation parameters have been investigated, and while previous meta-analyses have suggested that rTMS is efficacious, these have pooled different stimulation parameters and targets, and the relative efficacy of each is unknown. METHODS: We therefore performed a systematic review and network meta-analysis of randomized controlled trials (RCTs) by searching MEDLINE, EMBASE, CENTRAL, and PsycINFO and retaining RCTs with at least 5 individuals per arm and clinician-rated PTSD symptoms (PROSPERO CRD42019134984). We adhered to PRISMA guidelines, and 2 independent reviewers screened studies for eligibility and extracted the primary outcome of clinician-rated PTSD symptoms. Dropouts were extracted as a proxy for acceptability. Random effects pairwise meta-analyses and a network meta-analysis were performed. RESULTS: We synthesize data from 10 RCTs with a total of 421 participants. Two rTMS interventions targeting the right dorsolateral prefrontal cortex (DLPFC) improved PTSD symptoms relative to sham: low-frequency stimulation (SMD = 0.70; 95% CI, 0.22 to 1.18) and high-frequency stimulation (SMD = 0.71; 95% CI, 0.11 to 1.31). Medial PFC dTMS, right DLPFC intermittent theta-burst stimulation, and left DLPFC high-frequency stimulation did not separate from sham. Dropouts as a proxy for acceptability revealed no differences between any of the active conditions or sham nor did any of the active conditions differ from each other. CONCLUSION: The current literature does not support efficacy differences between interventions; however, protocols stimulating the right DLPFC appear superior to sham. It is unclear whether this reflects heterogeneity in pathology requiring a personalized medicine approach or nonspecific mechanisms of rTMS.
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment modality for Post-traumatic stress disorder (PTSD). Several targets and stimulation parameters have been investigated, and while previous meta-analyses have suggested that rTMS is efficacious, these have pooled different stimulation parameters and targets, and the relative efficacy of each is unknown. METHODS: We therefore performed a systematic review and network meta-analysis of randomized controlled trials (RCTs) by searching MEDLINE, EMBASE, CENTRAL, and PsycINFO and retaining RCTs with at least 5 individuals per arm and clinician-rated PTSD symptoms (PROSPERO CRD42019134984). We adhered to PRISMA guidelines, and 2 independent reviewers screened studies for eligibility and extracted the primary outcome of clinician-rated PTSD symptoms. Dropouts were extracted as a proxy for acceptability. Random effects pairwise meta-analyses and a network meta-analysis were performed. RESULTS: We synthesize data from 10 RCTs with a total of 421 participants. Two rTMS interventions targeting the right dorsolateral prefrontal cortex (DLPFC) improved PTSD symptoms relative to sham: low-frequency stimulation (SMD = 0.70; 95% CI, 0.22 to 1.18) and high-frequency stimulation (SMD = 0.71; 95% CI, 0.11 to 1.31). Medial PFC dTMS, right DLPFC intermittent theta-burst stimulation, and left DLPFC high-frequency stimulation did not separate from sham. Dropouts as a proxy for acceptability revealed no differences between any of the active conditions or sham nor did any of the active conditions differ from each other. CONCLUSION: The current literature does not support efficacy differences between interventions; however, protocols stimulating the right DLPFC appear superior to sham. It is unclear whether this reflects heterogeneity in pathology requiring a personalized medicine approach or nonspecific mechanisms of rTMS.
Authors: Jerome A Yesavage; J Kaci Fairchild; Zhibao Mi; Kousick Biswas; Anne Davis-Karim; Ciaran S Phibbs; Steven D Forman; Michael Thase; Leanne M Williams; Amit Etkin; Ruth O'Hara; Gerald Georgette; Tamara Beale; Grant D Huang; Art Noda; Mark S George Journal: JAMA Psychiatry Date: 2018-09-01 Impact factor: 21.596
Authors: Amit Etkin; Adi Maron-Katz; Wei Wu; Gregory A Fonzo; Julia Huemer; Petra E Vértes; Brian Patenaude; Jonas Richiardi; Madeleine S Goodkind; Corey J Keller; Jaime Ramos-Cejudo; Yevgeniya V Zaiko; Kathy K Peng; Emmanuel Shpigel; Parker Longwell; Russ T Toll; Allison Thompson; Sanno Zack; Bryan Gonzalez; Raleigh Edelstein; Jingyun Chen; Irene Akingbade; Elizabeth Weiss; Roland Hart; Silas Mann; Kathleen Durkin; Steven H Baete; Fernando E Boada; Afia Genfi; Jillian Autea; Jennifer Newman; Desmond J Oathes; Steven E Lindley; Duna Abu-Amara; Bruce A Arnow; Nicolas Crossley; Joachim Hallmayer; Silvia Fossati; Barbara O Rothbaum; Charles R Marmar; Edward T Bullmore; Ruth O'Hara Journal: Sci Transl Med Date: 2019-04-03 Impact factor: 17.956
Authors: Charles W Hoge; Rachel Yehuda; Carl A Castro; Alexander C McFarlane; Eric Vermetten; Rakesh Jetly; Karestan C Koenen; Neil Greenberg; Arieh Y Shalev; Sheila A M Rauch; Charles R Marmar; Barbara O Rothbaum Journal: JAMA Psychiatry Date: 2016-07-01 Impact factor: 21.596
Authors: Andrea Cipriani; Taryn Williams; Adriani Nikolakopoulou; Georgia Salanti; Anna Chaimani; Jonathan Ipser; Phil J Cowen; John R Geddes; Dan J Stein Journal: Psychol Med Date: 2017-12-19 Impact factor: 7.723
Authors: Andre R Brunoni; Anna Chaimani; Adriano H Moffa; Lais B Razza; Wagner F Gattaz; Zafiris J Daskalakis; Andre F Carvalho Journal: JAMA Psychiatry Date: 2017-02-01 Impact factor: 21.596